Sera Prognostics, Inc.

Sera Prognostics, Inc.

SERA·NASDAQ

$2.25

+9.5%
HealthcareMedical - Diagnostics & Research

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

At a Glance

Live Snapshot
Market Cap$85.74M
EPS-0.6700
P/E Ratio-3.35
Earnings Date08/05/2026

sera

Net Common Stock Issuance

Last Annual Value

54.22M

3-Year CAGR

%

5-Year CAGR

%

10-Year CAGR

51%

Sera Prognostics, Inc.

Sera Prognostics, Inc. Competitors Analysis of Net Common Stock Issuance

SERA · NASDAQ
CompanyNet Common Stock Issuance
CAGR 3Y
CAGR 5Y
CAGR 10Y
54.22M
N/A-4.0%N/A 
1.10M
N/A-63.3%N/A
9.54M
52.0%169.6%5.0%
-15.27K
N/AN/AN/A
DCGO logo
DocGo Inc.
NASDAQ:DCGO
-10.83M
N/AN/AN/A
75.21M
419.9%141.0%N/A
28.66M
27.4%-18.1%10.5%
3.01M
N/A-51.3%26.8%
658.00K
408.6%-52.2%-21.7%
58.67M
491.1%-5.5%N/A
21.92M
N/A31.4%10.0%
Sera Prognostics, Inc.

Sera Prognostics, Inc. Fair Value Envelope

SERA · NASDAQ

Our analysis suggests that SERA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $2.245, this represents a potential HIDDEN relative to our calculated worth for Sera Prognostics, Inc..

Intrinsic Value
Current Price: $2.245